谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Final Overall Survival Results from a Randomised, Phase III Study of Erlotinib Versus Chemotherapy As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-cell Lung Cancer (OPTIMAL, CTONG-0802).

C. Zhou,Y. L. Wu,G. Chen,J. Feng,X. -Q. Liu,C. Wang,S. Zhang,J. Wang,S. Zhou,S. Ren,S. Lu,L. Zhang,C. Hu,Y. Luo,L. Chen,M. Ye,J. Huang,X. Zhi, Y. Zhang,Q. Xiu,J. Ma,C. You

Annals of Oncology（2015）

引用 458|浏览67
关键词
chemotherapy,EGFR mutations,erlotinib,non-small-cell lung cancer,overall survival
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要